#United States #Chicago #Whitehawk #HWK-206 #SEZ6

Exciting Developments in Targeted Cancer Therapy at ASCO 2026

Whitehawk Therapeutics, Inc., a forward-thinking company dedicated to oncology therapeutics, recently made headlines at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago. On May 30, 2026, they unveiled compelling findings concerning the seizure-related homolog protein 6 (SEZ6), demonstrating its promise as a significant target in the treatment of small cell lung cancer (SCLC) and other neuroendocrine tumors. This revelation adds a new layer of potential to the landscape of cancer therapies.

SEZ6 is a transmembrane protein mainly expressed in central nervous system tissues and has shown a high expression rate in multiple neuroendocrine cancers. The data presented highlighted a robust correlation between SEZ6 expression levels and other established targets, particularly DLL3. This vital link paves the way for future combination therapy strategies that could significantly improve patient outcomes.

The real-world analysis conducted by Whitehawk highlighted that SEZ6 expression levels in SCLC surpass those of other approved and emerging antibody-drug conjugate (ADC) targets. Specifically, the expression of SEZ6 in SCLC was found to be at least three times higher than factors such as HER2, B7-H3, DLL3, PD-L1, and PD-1. The correlation with DLL3 reinforces the potential for developing combination treatments that leverage the strengths of both targets.

Dr. Afshin Dowlati from the University Hospitals Seidman Cancer Center, a key presenter at the event, claimed, "The impressive expression profile of SEZ6 is consistent across various stages of SCLC and even in metastatic settings. This consistency supports the view of SEZ6 as a promising candidate for ADC development."

Among the molecular subtypes of SCLC, SEZ6 was expressed most significantly in the SCLC-A and SCLC-N subtypes, which collectively account for around 90% of SCLC cases. This finding suggests that SEZ6's relevance is especially pronounced among patients with high neuroendocrine transcription factor expression.

HWK-206: The Future of Cancer Therapy

The focus now shifts to HWK-206, Whitehawk's innovative ADC designed to target SEZ6 specifically. Utilizing a dual epitope binding approach, HWK-206 is anticipated to enhance both binding and internalization rates compared to traditional single-epitope ADCs. Preclinical models have already indicated that HWK-206 could potentially outperform existing ADC treatments, a promising sign for patients battling tough-to-treat cancers.

Whitehawk expects to submit an Investigational New Drug (IND) application for HWK-206 in mid-2026, with plans to initiate Phase 1 clinical trials in the third quarter of 2026. Dr. Margaret Dugan, Whitehawk's Chief Medical Officer, expressed confidence in these developments, stating, "SEZ6's extensive expression profile reinforces our belief in its clinical significance for ADC targeting. Our data reinforces the relevance of HWK-206 in changing the treatment paradigm for SCLC and neuroendocrine tumors."

The primary findings regarding SEZ6 were shared during a dedicated poster session, with further details accessible on Whitehawk's official website. The collaboration between Whitehawk and Tempus AI has been pivotal in compiling this extensive analysis, marking a significant step forward in the fight against neuroendocrine tumors.

Conclusion

The insights provided at ASCO 2026 underline the importance of continuous research and innovation in oncology. Whitehawk Therapeutics’ commitment to exploring the therapeutic potential of SEZ6 and promoting the development of HWK-206 showcases the transformative promise of targeted therapies in improving patient lives. With experts backing the substantial findings and upcoming clinical trials, the oncology community is eager to witness how these developments will reshape treatment modalities for SCLC and other neuroendocrine tumors.